Cytek Biosciences, Inc. is a leading healthcare company based in the United States. With a Risk Rating Score of 29.0, it is considered to have a medium risk assessment. Cytek Biosciences is dedicated to revolutionizing cell analysis solutions using innovative technical approaches, particularly through its Cytek Aurora and Northern Lights systems. These cutting-edge flow cytometers offer full-spectrum analysis, enabling high-resolution, high-content, and high-sensitivity cell analysis. The company's FSP platform sets it apart by providing more detailed information, improved sensitivity, flexibility, and efficiency at a lower cost. With a focus on ESG principles, Cytek Biosciences is at the forefront of advancing healthcare technology.